[Form 4] Lexaria Bioscience Corp. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Lexaria Bioscience Corp. (LEXX) – Form 4 insider transaction

Director William E. McKechnie purchased 5,000 common shares on 07/29/2025 at $0.9063, increasing his direct ownership from 13,191 to 18,191 shares. No shares were sold or disposed of.

Table II lists unchanged holdings of 63,000 stock options with strike prices between $0.87 and $3.39, expiring from 2026-2030. The Form 4 was signed on 07/30/2025.

Insights

Financial Analyst

TL;DR: Director’s $0.9 share purchase modestly increases alignment; no sales reported.

The filing shows insider accumulation rather than disposition: 5,000 shares added at $0.9063 lifts McKechnie’s direct stake by roughly 38% to 18,191 shares. While the dollar amount is small, any open-market buy by a director generally signals confidence and tightens management-shareholder alignment. Existing option grants (63k) remain unchanged, so dilution implications are already known. Overall impact is mildly positive but not materially transformative.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

McKechnie William Edward

(Last) (First) (Middle)

235 WESTVALE DRIVE

(Street)

WATERLOO A6 N2T 1Y1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp. [ LEXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
common shares								13,191	D
common shares	07/29/2025		P		5,000	A	$0.9063	18,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3							04/26/2021	04/26/2026	Common Shares	1,500		1,500	D
Stock Options	$3							06/08/2021	06/08/2026	Common Shares	5,000		6,500	D
Stock Options	$3							09/01/2021	09/01/2026	Common Shares	1,900		8,400	D
Stock Options	$3.39							03/08/2022	03/08/2027	Common Shares	3,400		11,800	D
Stock Options	$1.96							10/12/2022	10/12/2027	Common Shares	18,200		30,000	D
Stock Options	$0.87							07/25/2023	07/25/2028	Common Shares	5,000		35,000	D
Stock Options	$2.36							04/26/2024	04/26/2029	Common Shares	5,000		40,000	D
Stock Options	$3.39							07/26/2024	07/26/2029	Common Shares	12,000		52,000	D
Stock Options	$1.04							05/15/2025	05/15/2030	Common Shares	11,000		63,000	D

Explanation of Responses:

	/William McKechnie/	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lexaria Bioscience (LEXX) report?

Director William E. McKechnie bought 5,000 common shares on 07/29/2025.

At what price were the shares purchased?

The shares were acquired at $0.9063 per share.

How many Lexaria shares does the director now own?

After the purchase, McKechnie directly holds 18,191 common shares.

Were any shares sold in this Form 4?

No. The filing records only an acquisition; no disposals were reported.

How many stock options does the director hold?

He owns 63,000 options with strike prices ranging from $0.87 to $3.39, expiring 2026-2030.